Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Treatment of Zollinger-Ellison syndrome Tomassetti P; Campana D; Piscitelli L; Mazzotta E; Brocchi E; Pezzilli R; Corinaldesi RWorld J Gastroenterol 2005[Sep]; 11 (35): 5423-32In this article, we have reviewed the main therapeutic measures for the treatment of Zollinger-Ellison syndrome (ZES). Review of the literature was based on computer searches (Pub-Med, Index Medicus) and personal experiences. We have evaluated all the measures now available for treating patients with sporadic gastrinomas or gastrinomas associated with Multiple Endocrine Neoplasia Type 1, (MEN 1) including medical therapy such as antisecretory drugs and somatostatin analogs (SST), chemotherapy and chemoembolization, and surgical procedures. In ZES patients, the best therapeutic procedure is surgery which, if radical, can be curative. Medical treatment can be the best palliative therapy and should be used, when possible, in association with surgery, in a multimodal therapeutic approach.|Antacids/therapeutic use[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Chemoembolization, Therapeutic[MESH]|Helicobacter pylori/pathogenicity[MESH]|Histamine H2 Antagonists/therapeutic use[MESH]|Humans[MESH]|Interferons/therapeutic use[MESH]|Multiple Endocrine Neoplasia Type 1/complications[MESH]|Proton Pump Inhibitors[MESH]|Somatostatin/analogs & derivatives[MESH]|Zollinger-Ellison Syndrome/complications/diagnosis/etiology/*therapy[MESH] |
